TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04610476
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab s.c. 1x 50 mg every 4 weeks
Study: NCT04610476
Drug: Abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks
Study: NCT01574157
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
Study: NCT00653848
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/square meter i.v. every third week, six cycles
Study: NCT03872427
Drug: Telaglenastat Hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Telaglenastat (DB15232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00998751
Drug: oral masitinib
Normalized name: axitinib Oral Product
DrugBank: Masitinib (DB11526)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg/day
Study: NCT00096148
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00096148
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04610476
Drug: Secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks
Study: NCT04610476
Drug: Ixekizumab
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab s.c. 1x 80 mg every 4 weeks
Study: NCT04610476
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks
Study: NCT00455117
Drug: Intravenous Parecoxib ('Dynastat' Pfizer)
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib or placebo
Study: NCT01369121
Drug: XERECEPT
DrugBank: Corticorelin acetate (DB12915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID dosing, subcutaneous for 1 year
Study: NCT03757650
Drug: Bismuth Subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
Study: NCT00248118
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During treatment phase, participants will take 300 mg bupropion or placebo daily.
Study: NCT04315688
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Tresiba® with or without anti-diabetes medication (as per local label), as prescribed by the participant's physician. The study population will include adult patients with type 2 diabetes, both insulin naïve and previously insulin treated, for whom the treating physician has decided to initiate treatment with Tresiba®, independent of the decision to include the patient in the study.
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 5 mg, Single dose, 1 day
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 20 mg, Single dose, 1 day
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 60 mg, Single dose, 1 day
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 150 mg, Single dose, 1 day
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 300 mg, Single dose, 1 day
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 600 mg, Single Dose, 1 day
Study: NCT01049165
Drug: [14C] BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 150 mg, Single Dose, 1 day
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 1200 mg, Single dose, 1 day
Study: NCT01049165
Drug: BMS-813160
Normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution, Oral, 2000 mg, Single Dose, 1 day
Study: NCT00373165
Drug: Ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00024427
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Normal dose to treat pancreatic cancer
Study: NCT00024427
Drug: triacetyluridine
Normalized name: Triacetyluridine
DrugBank: Uridine triacetate (DB09144)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 grams (12 tablets)
Study: NCT04088448
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
Study: NCT02862691
Drug: Bupivicaine (Injectable local anesthetic)
Normalized name: Gelato Anesthetic
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
Study: NCT00359944
Drug: AC-3933
Normalized name: Ac
DrugBank: Actinium (DB12860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg twice daily
Study: NCT00359944
Drug: AC-3933
Normalized name: Ac
DrugBank: Actinium (DB12860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-3933, 20 mg twice daily
Study: NCT00003234
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003103
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00521430
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00521430
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00521430
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00521430
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00585221
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continue imatinib until progression.
Study: NCT00068250
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2, intravenously three days prior to the first cycle of methotrexate
Study: NCT00068250
Drug: temozolomide 100 mg/m^2
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
Study: NCT00068250
Drug: temozolomide 150 mg/m^2
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
Study: NCT00068250
Drug: temozolomide 200 mg/m^2
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
Study: NCT00068250
Drug: post-radiation therapy temozolomide
Normalized name: lidocaine
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
Study: NCT00620425
Drug: Sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection
Study: NCT01824823
Drug: afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00895414
Drug: enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
Study: NCT00000146
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000146
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00420615
Drug: Patupilone and Omeprazole
Normalized name: omeprazole, amoxicillin and rifabutin
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00420615
Drug: Patupilone + Midalzolam
Normalized name: Midazolam
DrugBank: Patupilone (DB03010)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03342573
Drug: Cosentyx
Normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
Study: NCT03404804
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
Study: NCT02956044
Drug: Bexagliflozin
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexagliflozin tablets, 20 mg
Study: NCT02956044
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg metformin
Study: NCT02956044
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg glimepiride
Study: NCT02956044
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg sitagliptin
Study: NCT00559468
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
Study: NCT00559468
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
Study: NCT00559468
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
Study: NCT00559468
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
Study: NCT01593995
Drug: Epidermal growth factor (EGF) ointment
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect
Study: NCT00679458
Drug: buprenorphine alone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
Study: NCT00931723
Drug: Quetiapine fumarate XR
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
Study: NCT00931723
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
Study: NCT01414101
Drug: ISIS CRP Rx or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01165112
Drug: Bendamustine Hydrochloride
Normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01165112
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01165112
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03937648
Drug: COL-144 50mg
Normalized name: Col-118
DrugBank: Col-118 (DB05778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-144 50mg
Study: NCT03937648
Drug: COL-144 100mg
Normalized name: Col-118
DrugBank: Col-118 (DB05778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-144 100mg
Study: NCT03937648
Drug: COL-144 200mg
Normalized name: Col-118
DrugBank: Col-118 (DB05778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-144 200mg
Study: NCT03937648
Drug: COL-144 400mg
Normalized name: Col-118
DrugBank: Col-118 (DB05778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-144 400mg
Study: NCT01683006
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering.
Study: NCT04600505
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.
Study: NCT01518998
Drug: Fimasartan , Amlodipine, Placebo
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
Study: NCT01926171
Drug: Icotinib plus WBRT
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
Study: NCT02250807
Drug: Simeprevir
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
Study: NCT02250807
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
Study: NCT04073784
Drug: Gemcitabine combined with Aptinib and Toripalimab
Normalized name: Toripalimab
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance.
Study: NCT00199316
Drug: spinal morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03876015
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT00907803
Drug: ST-246 400 mg
Normalized name: STS
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, 400 mg daily for 14 days
Study: NCT00907803
Drug: ST-246 600 mg
Normalized name: STS
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, 600 mg daily for 14 days
Study: NCT01010568
Drug: Ofatumumab and Bendamustine
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
Study: NCT03510468
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each tablet contains 25 mg of tenofovir alafenamide.
Study: NCT03510468
Drug: Rifapentine
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
Study: NCT03510468
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each tablet is formulated as 100 or 300 mg of isoniazid.
Study: NCT02995083
Drug: 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
Study: NCT02995083
Drug: Air 10 ml
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
Study: NCT00888355
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
Study: NCT01448824
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04618042
Drug: FX06
Normalized name: FX06
DrugBank: FX06 (DB05685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
Study: NCT04618042
Drug: Placebo of FX06
DrugBank: FX06 (DB05685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
Study: NCT00713921
Drug: Fesoterodine Oral Product
Normalized name: fesoterodine Oral Product
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
Study: NCT04067037
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04067037
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04067037
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04067037
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Study: NCT04656795
Drug: MT-7117
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-7117
Study: NCT03633630
Drug: Amla
Normalized name: Amlactin
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Study: NCT03711929
Drug: DE-109 Intravitreal Injections
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 440 ug of DE-109 Injectable Solution
Study: NCT03711929
Drug: DE-109 Intravitreal Injections
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
Study: NCT03711929
Drug: DE-109 Intravitreal Injections (Open Label)
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)